Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Up 5.6% in September

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) was the recipient of a significant increase in short interest in the month of September. As of September 15th, there was short interest totalling 478,300 shares, an increase of 5.6% from the August 31st total of 452,800 shares. Based on an average trading volume of 61,400 shares, the short-interest ratio is presently 7.8 days. Approximately 3.5% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price objective on shares of Acurx Pharmaceuticals in a report on Monday, August 12th.

Institutional Investors Weigh In On Acurx Pharmaceuticals

A hedge fund recently raised its stake in Acurx Pharmaceuticals stock. Prospect Financial Services LLC grew its position in Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) by 1.9% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 278,100 shares of the company’s stock after buying an additional 5,250 shares during the period. Prospect Financial Services LLC owned 1.76% of Acurx Pharmaceuticals worth $626,000 at the end of the most recent quarter. Institutional investors and hedge funds own 11.53% of the company’s stock.

Acurx Pharmaceuticals Stock Up 1.1 %

Acurx Pharmaceuticals stock opened at $1.92 on Wednesday. The company’s 50-day moving average price is $2.06 and its 200-day moving average price is $2.16. The company has a market cap of $30.42 million, a PE ratio of -1.63 and a beta of -1.72. Acurx Pharmaceuticals has a twelve month low of $1.17 and a twelve month high of $8.82.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. During the same quarter in the previous year, the business earned ($0.28) EPS. As a group, sell-side analysts expect that Acurx Pharmaceuticals will post -0.98 earnings per share for the current fiscal year.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.